

Honolulu, Hawaii

Feb 29, 2008

RE: H.B. No. 12

H.D. 2

Honorable Calvin K.Y. Say
Speaker, House of Representatives
Twenty-Fourth State Legislature
Regular Session of 2008
State of Hawaii

Sir:

Your Committee on Finance, to which was referred H.B. No. 12, H.D. 1, entitled:

"A BILL FOR AN ACT RELATING TO PRESCRIPTION DRUG COST CONTAINMENT AND AFFORDABLE ACCESS,"

begs leave to report as follows:

The purpose of this bill is to protect consumers by requiring pharmaceutical manufacturing companies to disclose to the Board of Pharmacy (Board), gifts, fees, payments, and subsidies, or other economic benefits in connection with detailing, promotional, or other marketing activities by the company to physicians, hospitals, nursing homes, pharmacists, health plan administrators, or others who are authorized to prescribe, dispense, or sell prescription drugs in the state.

The Hawaii Alliance for Retired Americans and ILWU Local 142 testified in support of this bill. The Pharmaceutical Research and Manufacturers of America testified in opposition to this measure. The Office of Information Practices submitted comments.

Your Committee has amended this bill by;


- (1) Clarifying that the initial disclosure to the Board shall be made prior to December 31, 2009, for the twelve month period ending June 30, 2009;



- (2) Establishing timelines for subsequent annual disclosures by pharmaceutical marketers;
- (3) Clarifying that the initial disclosure of the name and address of the individual responsible for the pharmaceutical manufacturing company's compliance with this new law shall be made before October 1, 2009; and
- (4) Making technical, nonsubstantive amendments for clarity, consistency, and style.

As affirmed by the record of votes of the members of your Committee on Finance that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 12, H.D. 1, as amended herein, and recommends that it pass Third Reading in the form attached hereto as H.B. No. 12, H.D. 2.

Respectfully submitted on
behalf of the members of the
Committee on Finance,


MARCUS R. OSHIRO, Chair



